MiMedx Group (NASDAQ:MDXG) Shares Up 7.8% – Should You Buy?

MiMedx Group, Inc (NASDAQ:MDXG) rose 7.8% during mid-day trading on Monday . The stock traded as high as $4.44 and last traded at $4.4510. 173,992 shares changed hands during trading, a decline of 87% from the average daily volume of 1,315,922 shares. The stock had previously closed at $4.13.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on MDXG. Citizens Jmp decreased their price objective on shares of MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating for the company in a research report on Thursday, April 30th. Wall Street Zen downgraded shares of MiMedx Group from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings downgraded MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 18th. Finally, Craig Hallum cut their price objective on MiMedx Group from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $8.50.

MiMedx Group Stock Performance

The stock has a market capitalization of $637.70 million, a price-to-earnings ratio of 109.40 and a beta of 1.45. The company’s fifty day simple moving average is $3.92 and its 200 day simple moving average is $4.23. The company has a quick ratio of 4.79, a current ratio of 5.33 and a debt-to-equity ratio of 0.07.

MiMedx Group (NASDAQ:MDXG) last posted its earnings results on Wednesday, July 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05). The company had revenue of $64.36 million during the quarter, compared to analysts’ expectations of $63.46 million. MiMedx Group had a net margin of 1.76% and a return on equity of 12.09%. On average, equities research analysts expect that MiMedx Group, Inc will post -0.09 earnings per share for the current year.

Institutional Investors Weigh In On MiMedx Group

Hedge funds have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC grew its position in shares of MiMedx Group by 433.2% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 289,199 shares of the company’s stock valued at $1,958,000 after purchasing an additional 234,958 shares during the last quarter. Hillsdale Investment Management Inc. acquired a new stake in MiMedx Group during the 4th quarter worth approximately $7,134,000. Renaissance Technologies LLC boosted its stake in MiMedx Group by 22.4% in the 1st quarter. Renaissance Technologies LLC now owns 3,019,871 shares of the company’s stock valued at $11,928,000 after purchasing an additional 552,806 shares during the period. Vanguard Group Inc. boosted its stake in MiMedx Group by 5.6% in the 4th quarter. Vanguard Group Inc. now owns 7,184,262 shares of the company’s stock valued at $48,637,000 after purchasing an additional 382,623 shares during the period. Finally, OP Asset Management Ltd acquired a new position in MiMedx Group in the 1st quarter valued at $2,406,000. 79.15% of the stock is currently owned by institutional investors and hedge funds.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.